Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 486 participants.

Also called NCT01623115

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 486 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01623115
  • EudraCT 2011-005109-56
Other papers using this trial's data
  • ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia European heart journal, 2015-11-14 DOI, PubMed 26330422, PMC4644253 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Canada, Czechia, Denmark, France, Israel, Netherlands, Norway, Russia, South Africa, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01623115. Randomized; quadruple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2015-11-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Acronym
ODYSSEY FH I
Condition
Hypercholesterolemia
Intervention (Drug)
Alirocumab
Intervention (Drug)
Placebo (for alirocumab)
Intervention (Drug)
Lipid Modifying Therapy (LMT)
Lead sponsor
Sanofi (class: industry)
Collaborator
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01623115
Content hash
487ae1ff9be0a3710b656429c351f91af57fd73be6f4cd290591c60048622575